Boehringer Ingelheim Gmbh

Herbert Stricker

Peter Gruber

Rolf Stefan Brickl

Gerhard Bozler

Dietrich Arndts

Bernhard Freund

Wolf D Bechtel

Siegfried Darda

Karl L Rominger

Heribert Harwalik

Volkmar Haselbarth

Bernd Zierenberg

Dieter Bendix

Gunther Entenmann

Otto Kern

Michel Mikhail

The invention relates to an implantable biodegradable system for releasing active substance.

Implantable, biodegradable system for releasing active substance

The invention relates to a process for preparing poly-D,L-lactide and its use as a carrier for active substances.

Process for preparing poly-D,L-lactide and the use thereof as a carrier

This invention relates to a pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing (1) a disintegrating core comprising clonidine, said disintegrating core having a readily water-soluble coating, and (2) a plurality of non-disintegrating cores comprising clonidine, said non-disintegrating cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the disintegrating and non-disintegrating cores being at least about 5 mm.

Retard form of pharmaceuticals with insoluble porous diffusion coatings

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, where the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

This invention is directed to a pharmaceutical preparation for transdermal application, which comprises a film comprising a skin-compatible polyacrylate, which swells in water and a pharmaceutically active substance in amorphous form. The invention is also directed to the preparation of said pharmaceutical preparation and its use in administering pharmaceutically active substances.

Transdermal release system for pharmaceutical preparation

This invention relates to a composition for the sustained release of dipyridamole which comprises (i) spheroid particles comprised of dipyridamole or crystallized salts thereof and pharmacologically acceptable acid or acid substance, and (ii) a coating surrounding said spheroid particles, said coating being comprised of from about 50 to 100 percent by weight of acid-insoluble lacquers soluble in intestinal juices and from about 0 to 50 percent by weight of lacquers insoluble in gastric and intestinal juices and said coating being present in an amount of from about 3 to 30 percent by weight, based on the weight of the spheroid particles, and to the preparation of such a composition.

Dipyricamole sustained release forms comprising lacquer-coated particles

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, were the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

Growing community of inventors

Ingelheim, Germany

Herbert Stricker